JP5633028B2 - Sympathetic nerve activator - Google Patents

Sympathetic nerve activator Download PDF

Info

Publication number
JP5633028B2
JP5633028B2 JP2013143531A JP2013143531A JP5633028B2 JP 5633028 B2 JP5633028 B2 JP 5633028B2 JP 2013143531 A JP2013143531 A JP 2013143531A JP 2013143531 A JP2013143531 A JP 2013143531A JP 5633028 B2 JP5633028 B2 JP 5633028B2
Authority
JP
Japan
Prior art keywords
black ginger
sympathetic nerve
administration
extract
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013143531A
Other languages
Japanese (ja)
Other versions
JP2014031367A (en
Inventor
仁人 鍔田
仁人 鍔田
寛 友澤
寛 友澤
高垣 欣也
欣也 高垣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyo Shinyaku Co Ltd
Original Assignee
Toyo Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Shinyaku Co Ltd filed Critical Toyo Shinyaku Co Ltd
Priority to JP2013143531A priority Critical patent/JP5633028B2/en
Publication of JP2014031367A publication Critical patent/JP2014031367A/en
Application granted granted Critical
Publication of JP5633028B2 publication Critical patent/JP5633028B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Description

本発明は、交感神経活発化剤に関する。   The present invention relates to a sympathetic nerve activator.

自律神経は、交感神経系と副交感神経系で構成されており、これら二つの神経系のバランスにより、血管、内臓の働きをコントロールし、体内の環境を整え、さらには呼吸、血液循環、消化吸収、排泄、内分泌、熱産生等のシステムを調整し、生命維持に必要な体内循環を整える役割を果たしている。加齢、体調不良、疾病やストレス、疲労等により交感神経系と副交感神経系のバランスが崩れると、頭痛、吐き気、耳鳴り、微熱、震え、耳鳴り、立ち眩み、血管収縮や疲労感や汗を異常にかく等の症状が現れてくる。また、精神的にも、人間不信、情緒不安定、不安感やイライラ、抑うつ気分等を引き起こす原因となる。   The autonomic nervous system is composed of the sympathetic nervous system and the parasympathetic nervous system. The balance of these two nervous systems controls the functions of blood vessels and internal organs, regulates the internal environment, and further breathes, circulates blood, digestive and absorption. It plays a role in regulating the systemic system such as excretion, endocrine secretion, heat production, etc., and adjusting the body circulation necessary for life support. If the balance between the sympathetic nervous system and parasympathetic nervous system is lost due to aging, poor physical condition, disease, stress, fatigue, etc., headache, nausea, tinnitus, slight fever, trembling, tinnitus, tinnitus, dizziness, vasoconstriction, fatigue and sweat are abnormal Symptoms such as anyway appear. It also causes mental distrust, emotional instability, anxiety, irritation, and depression.

従来より、このような症状に対し、摂取により自律神経の活動を上昇させるものとして、唐辛子や生姜等の辛味成分が知られているが、いずれも辛いことや胃腸への刺激が強いことから、食品として一度に多量に摂取することができず、有効に自律神経の活動を上昇させることは困難であった。これらに代わるものとして、近年において、様々な植物の抽出物の適用が試みられてきた(特許文献1〜3)。   Conventionally, symptom components such as chili and ginger are known to increase autonomic nervous activity by ingestion for such symptoms, but both are spicy and strong gastrointestinal irritation, It was difficult to take a large amount of food as a food at once, and it was difficult to effectively increase autonomic nerve activity. As an alternative to these, application of various plant extracts has been attempted in recent years (Patent Documents 1 to 3).

特開平11−302166号公報JP-A-11-302166 特開2002−145765号公報JP 2002-145765 A 特開2011−178741号公報JP 2011-178741 A

しかしながら、これらの植物の抽出物は、交感神経系と副交感神経系のいずれの神経系を増進あるいは抑制するのかは明らかでなく、様々な症状や目的に対する、よりきめ細やかな処方を行うためには不十分であった。   However, it is not clear whether these plant extracts enhance or suppress the nervous system of the sympathetic nervous system or the parasympathetic nervous system, and in order to make a more detailed prescription for various symptoms and purposes It was insufficient.

本発明は、交感神経系の働きを増進させる交感神経活発化剤を提供することを目的とする。   An object of this invention is to provide the sympathetic nerve activator which improves the function of a sympathetic nervous system.

本発明者らは、黒生姜の根茎の粉砕物、根茎の絞り汁又は抽出物、これらの乾燥物、あるいは、その粉末化物等の黒生姜の根茎、茎、葉又は花等の加工物が、交感神経系の働きを増進させることを見出し、本発明を完成するに至った。より具体的には、本発明は以下のようなものを提供する。   The inventors of the present invention are ground ginger rhizomes, rhizome juice or extract, dried products thereof, or processed products such as ginger rhizomes, stems, leaves or flowers. The inventors have found that the function of the sympathetic nervous system is enhanced, and have completed the present invention. More specifically, the present invention provides the following.

(1)黒生姜加工物品を含有することを特徴とする交感神経活発化剤。 (1) A sympathetic nerve activator comprising a black ginger processed article.

(2)前記黒生姜加工物品が黒生姜の根茎を利用したものである(1)記載の交感神経活発化剤。 (2) The sympathetic nerve activator according to (1), wherein the black ginger processed article uses a black ginger rhizome.

本願発明の交感神経活発化組成物を摂ることにより、自律神経の乱れのある場合、特に相対的に副交感神経系が優位な場合に、これを改善することができる。また、尿の抑制、血圧の上昇、心拍数の上昇を目的として使用することが可能である。 By taking the sympathetic nerve activation composition of the present invention, this can be improved when there is a disturbance of the autonomic nerve, particularly when the parasympathetic nervous system is relatively dominant. Further, suppression of urination, increased blood pressure, it is possible to use an increase in heart rate purposes.

マウスの褐色脂肪組織交感神経活動(BAT−SNA)の経時変化を示す。2 shows the time course of brown adipose tissue sympathetic nerve activity (BAT-SNA) in mice. マウスの大腿皮膚動脈交感神経活動(CASNA)の経時変化を示す。2 shows time course of femoral cutaneous sympathetic nerve activity (CASNA) in mice. マウスの褐色脂肪組織交感神経活動(BAT−SNA)の経時変化を示す。2 shows the time course of brown adipose tissue sympathetic nerve activity (BAT-SNA) in mice.

以下、本発明の実施形態について説明する。   Hereinafter, embodiments of the present invention will be described.

本願発明で用いられる黒生姜(Kaempferia Parviflora)とは東南アジアに自生するショウガ科、バンウコン属の植物で、精力増進、滋養強壮、血糖値の低下、体力回復、消化器系の改善、膣帯下、痔核、痔疾、むかつき、口内炎、関節痛、胃痛の改善等の報告がある。このように、黒生姜は、長期にわたり人間に摂取されてきた実績のある天然植物あって安全性が高い。そのため、当該組成物は、実用性が高く、医薬部外品、医薬品、外用剤等に幅広く使用することができる。   Kaempferia Parviflora used in the present invention is a plant belonging to the genus Ginger, genus Van turf that grows naturally in Southeast Asia. There have been reports of improvements in hemorrhoids, hemorrhoids, nausea, stomatitis, joint pain, and stomach pain. In this way, black ginger is a highly safe natural plant with a proven track record that has been ingested by humans over a long period of time. Therefore, the composition has high practicality and can be widely used for quasi drugs, pharmaceuticals, external preparations and the like.

本発明の加工物品を得るための黒生姜の使用部位は樹皮、根、葉、茎、花又は枝等が使用し得る。なかでも、好ましいのは、根茎である。具体的には、黒生姜の加工品(乾燥物、裁断物等)あるいはその粉末、絞り汁又は抽出物を利用することができる。なお、ここで、抽出物とは、上記黒生姜又はその加工物を溶媒で抽出して得られる抽出液、その希釈液又は濃縮液、あるいはそれらの乾燥物及びその粉末を意味する。薬品として使用する点等を考慮すると、抽出物を用いることも好ましい。本発明において、加工物品とは、これらのすべてを包含する。 Bark, roots, leaves, stems, flowers, branches, and the like can be used as the part where black ginger is used to obtain the processed article of the present invention. Among them, preferred is a rhizome. Specifically, black ginger processed products (dried products, cut products, etc.) or powders, juices or extracts thereof can be used. Here, the extract means an extract obtained by extracting the black ginger or processed product thereof with a solvent, a diluted solution or a concentrated solution thereof, or a dried product thereof and a powder thereof. Considering the points or the like to be used as medicines, it is also preferable to use an extract. In the present invention, the processed article includes all of them.

黒生姜の粉末製品は、洗浄後、スライスした黒生姜を天日、あるいは乾燥機を用いて乾燥後、そのままあるいは適当な形状大きさに裁断して得た加工品を、粉砕装置を用いて粉砕することで得ることができる。粉砕装置としては通常使用されるものがひろく使用できるが、例えば、原料ホッパー、粉砕機、分級機及び製品ホルダー等から構成される粉砕機を用いることができる。   Black ginger powder products are washed, and the sliced black ginger is dried using the sun or a dryer, and then processed as it is or cut into an appropriate shape and size using a pulverizer. You can get it. As the pulverizer, those usually used can be widely used. For example, a pulverizer composed of a raw material hopper, a pulverizer, a classifier, a product holder and the like can be used.

黒生姜の抽出物は、黒生姜又はその加工物を溶媒で抽出することによって得られる。抽出に使用される溶媒としては、エタノール、メタノール、イソプロパノール、ブタノール等の低級アルコール、酢酸エチル、酢酸メチル等の低級エステル、アセトン、及びこれらと水との混合溶媒が挙げられる。水のみで行うことも有効である。中でも、本発明の組成物がヒトが摂取するものであることから、水単独又はエタノール単独、若しくは水とエタノールとの混合溶媒(いわゆる含水エタノール)を使用するのが好ましい。特に、40%以上の濃度で、エタノールを含む混合溶媒を使用するのが好ましい。   An extract of black ginger is obtained by extracting black ginger or a processed product thereof with a solvent. Examples of the solvent used for extraction include lower alcohols such as ethanol, methanol, isopropanol, and butanol, lower esters such as ethyl acetate and methyl acetate, acetone, and a mixed solvent of these with water. It is also effective to use water alone. Among these, since the composition of the present invention is ingested by humans, it is preferable to use water alone, ethanol alone, or a mixed solvent of water and ethanol (so-called hydrous ethanol). In particular, it is preferable to use a mixed solvent containing ethanol at a concentration of 40% or more.

溶媒として混合溶媒を使用する場合は、例えば、アセトン/水(2/8〜8/2、体積比)混合物、エタノール/水(2/8〜8/2、体積比)混合物等を用いることもできる。エタノール/水の場合、黒生姜の根茎に対して、その質量の2〜20倍質量の溶媒を加え、室温又は加熱下で10分〜48時間程度抽出するのが好ましい。   When a mixed solvent is used as the solvent, for example, an acetone / water (2/8 to 8/2, volume ratio) mixture, an ethanol / water (2/8 to 8/2, volume ratio) mixture, or the like may be used. it can. In the case of ethanol / water, it is preferable to add a solvent having a mass of 2 to 20 times the mass of black ginger rhizome and extract it at room temperature or under heating for about 10 minutes to 48 hours.

用いる抽出方法に特に制限はないが、安全性及び利便性の観点から、できるだけ緩やかな条件で行うことが好ましい。例えば、原料植物部位又はその乾燥物を粉砕、破砕又は細断し、これに2〜20倍質量の溶媒を加え、0℃〜溶媒の還流温度の範囲で10分〜48時間、静置、振盪、攪拌あるいは還流等の任意の条件下にて抽出を行う。抽出作業後、濾過、遠心分離等の分離操作を行い、不溶物を除去する。これに、必要に応じて希釈、濃縮操作を行うことにより、抽出液を得る。さらに、不溶物についても同じ操作を繰り返して抽出し、その抽出液を先の抽出液と合わせて用いてもよい。これらの抽出物は、当業者が通常用いる精製方法により、さらに精製して使用してもよい。   There is no particular limitation on the extraction method to be used, but from the viewpoint of safety and convenience, the extraction method is preferably performed under as mild a condition as possible. For example, pulverize, crush or shred the raw material plant part or its dried product, add 2 to 20 times the mass of the solvent, and leave it at 0 ° C. to the reflux temperature of the solvent for 10 minutes to 48 hours. The extraction is performed under any conditions such as stirring or refluxing. After the extraction operation, separation operations such as filtration and centrifugation are performed to remove insoluble matters. An extract is obtained by diluting and concentrating as necessary. Further, the same operation may be repeated for insoluble matter, and the extract may be used in combination with the previous extract. These extracts may be used after further purification by a purification method commonly used by those skilled in the art.

得られた抽出液は、そのままあるいは濃縮して、液状物、濃縮物、ペースト状で、あるいは、さらにこれらを乾燥した乾燥物の形状で用いることができる。乾燥は、噴霧乾燥、凍結乾燥、減圧乾燥、流動乾燥等の当業者が通常用いる方法により行われる。さらに、以上の方法で得られた乾燥物品を、周知の方法を用いて粉末化して使用することも可能である。   The obtained extract can be used as it is or after being concentrated to form a liquid, a concentrate, a paste, or a dried product obtained by further drying these. Drying is performed by a method commonly used by those skilled in the art, such as spray drying, freeze drying, reduced pressure drying, and fluidized drying. Furthermore, it is also possible to use the dried article obtained by the above method by pulverizing it using a known method.

本願発明の交感神経活発化剤は、交感神経系の働きを増進させることから、排尿の抑制、血圧の上昇、心拍数の上昇を目的として、動物あるいはヒトに与えることができる。 Since the sympathetic nerve activator of the present invention enhances the function of the sympathetic nervous system, it can be given to animals or humans for the purpose of suppressing urination, increasing blood pressure, and increasing heart rate.

本願発明の交感神経活発化剤は、上記した目的に応じ、非経口投与剤、経口投与剤等として、そのまま、あるいは、他の成分と混合して使用することができる。非経口投与剤としては、静脈内投与剤、筋肉内投与剤、皮下投与剤、経皮投与剤、等が用いられる。皮下投与剤のひとつである、腹腔内投与剤としてもよい。また、経腸投与剤として、注射等を用い内臓へ直接投与することも好ましい。   The sympathetic nerve activator of the present invention can be used as it is or as a mixture with other components as a parenteral agent, an oral agent and the like according to the above-mentioned purpose. As parenteral administration agents, intravenous administration agents, intramuscular administration agents, subcutaneous administration agents, transdermal administration agents, and the like are used. It is good also as an intraperitoneal administration agent which is one of the subcutaneous administration agents. Moreover, it is also preferable to administer directly to the internal organs by injection etc. as an enteral agent.

また、本願発明の交感神経活発化剤は、化粧品に適した形態として使用することもできる。例えば、ローション剤、乳剤、ゲル剤、クリーム剤、軟膏剤等の種々の形態に加工され得る。具体的には、化粧水、化粧クリーム、乳液、クリーム、パック、ヘアトニック、ヘアクリーム、シャンプー、ヘアリンス、トリートメント、洗顔剤、ファンデーション、育毛剤、水性軟膏、スプレー等として利用できる。   Moreover, the sympathetic nerve activator of this invention can also be used as a form suitable for cosmetics. For example, it can be processed into various forms such as lotions, emulsions, gels, creams, ointments and the like. Specifically, it can be used as a lotion, cosmetic cream, milky lotion, cream, pack, hair tonic, hair cream, shampoo, hair rinse, treatment, facial cleanser, foundation, hair restorer, aqueous ointment, spray and the like.

黒生姜の成分の変性防止の観点からは非経口投与剤とする方法もあるが、黒生姜の成分は有機溶剤による抽出にも耐えられるほど丈夫で、胃液等への暴露によっても変性しにくいため、経口投与剤としても十分な効果を得ることができる。経口投与剤としては、例えば、錠剤、顆粒剤、散剤、カプセル等がある。カプセル化して、内臓にそのまま到達させる量を増やすことが好ましい。さらに、本発明の一剤は、錠剤、散剤、カプセル等の剤形状を有するもののほか、ドリンク剤、シロップ剤、ゼリーの形で供給され得る。   Although there is a method for parenteral administration from the viewpoint of preventing the degeneration of black ginger components, the components of black ginger are strong enough to withstand extraction with organic solvents and are not easily denatured by exposure to gastric juice. A sufficient effect can also be obtained as an oral administration agent. Examples of the orally administered agent include tablets, granules, powders, and capsules. It is preferable to encapsulate and increase the amount that reaches the internal organs as it is. Furthermore, one agent of the present invention can be supplied in the form of drinks, syrups, and jelly, in addition to those having dosage forms such as tablets, powders, and capsules.

経口投与剤としては、例えば、当業者が通常用いる添加剤(例えば、デキストリン、デンプン、糖類、リン酸カルシウム等の賦形剤、香料、香油等)を用いて、錠剤、顆粒剤等の形状に成形してもよく、あるいは、水、飲料等に溶解して、液剤としてもよい。好ましくは、カプセル剤、顆粒剤、錠剤又は飲料の形態である。   As an orally administered agent, for example, it is formed into a tablet, granule, etc. using additives usually used by those skilled in the art (for example, excipients such as dextrin, starch, saccharides, calcium phosphate, fragrance, perfume oil, etc.). Alternatively, it may be dissolved in water, beverage or the like to form a liquid. Preferably, it is in the form of a capsule, granule, tablet or beverage.

カプセル剤の製造方法としては、内容物として上記植物又は抽出物を用いること以外は、従来公知のソフトカプセルの製造方法に従えばよい。そのような製造法としては、カプセル皮膜シートを用いて、ロータリー式充填機で内容物を封入し、カプセル製剤を成型する方法、又は滴下法によりシームレスカプセルを製造する方法等が挙げられる。   As a method for producing a capsule, a conventionally known method for producing a soft capsule may be used except that the plant or the extract is used as the content. Examples of such a production method include a method of encapsulating contents with a rotary filling machine using a capsule film sheet and molding a capsule preparation, or a method of producing seamless capsules by a dropping method.

また、錠剤については、上記植物又は抽出物を含有する顆粒あるいは抽出物そのものに、適切な結合剤、賦形剤、崩壊剤及び必要に応じて滑沢剤を添加し、公知の打錠法により調製することができる。顆粒剤については、公知の各種湿式、乾式等の造粒法が適用でき、適切な結合剤及び賦形剤とともに成形する。さらに、ドリンク剤、シロップ剤、ゼリー等については、適切な糖、酸、香料等を添加して香味を調整し、公知の製法により調製することができる。   For tablets, add appropriate binders, excipients, disintegrants and lubricants as necessary to the granules containing the plant or the extract or the extract itself, and use a known tableting method. Can be prepared. As for the granule, known various wet and dry granulation methods can be applied, and it is molded together with an appropriate binder and excipient. Furthermore, drinks, syrups, jellies and the like can be prepared by adding known sugars, acids, fragrances and the like to adjust the flavor and preparing them by known production methods.

本発明の交感神経活発化剤に含有される黒生姜加工物品の配合量としては特に制限はないが、経口投与剤であれば、好ましくは0.0001%以上、より好ましくは0.001%以上配合されることが望ましく、化粧品等の非経口投与剤であれば、好ましくは0.00001%以上、より好ましくは0.0001%以上配合されることが望ましい。   The blending amount of the black ginger processed article contained in the sympathetic nerve activator of the present invention is not particularly limited, but is preferably 0.0001% or more, more preferably 0.001% or more if it is an oral administration agent. In the case of a parenteral administration agent such as cosmetics, it is desirable to be blended preferably 0.00001% or more, more preferably 0.0001% or more.

次に、本発明を実施例に基づいてさらに詳細に説明するが、本発明はこれに限定されるものではない。   Next, the present invention will be described in more detail based on examples, but the present invention is not limited thereto.

(黒生姜抽出液の製造)
黒生姜の根茎チップ300gを秤量し、60%エタノール3lとともに3角フラスコに入れる。途中で何回か攪拌しながら室温で24時間静置する。減圧濾過後、残ったチップに60%エタノール3lに再度浸漬して、室温で24時間静置して抽出を行う。これを減圧濾過して、2回目の抽出液を得た。前記1回目、2回目の抽出液を併せ、これを約1/6に減圧濃縮して原液とした。
(Manufacture of black ginger extract)
300 g of black ginger rhizome chips are weighed and placed in a triangular flask together with 3 l of 60% ethanol. Allow to stand at room temperature for 24 hours while stirring several times along the way. After filtration under reduced pressure, the remaining chip is dipped again in 3 l of 60% ethanol and left to stand at room temperature for 24 hours for extraction. This was filtered under reduced pressure to obtain a second extract. The first and second extracts were combined and concentrated under reduced pressure to about 1/6 to obtain a stock solution.

(交感神経活動評価試験)
12時間毎の明暗周期(8時〜20時まで点灯)下に24℃の恒温動物室にて1週間以上飼育した体重約300gのWistar系雄ラット(約9週齢)を使用した。実験当日は3時間絶食させた後ウレタン麻酔し、十二指腸投与用のカニューレを挿入し、その後、肩甲間褐色脂肪組織交感神経、大腿皮膚動脈交感神経の遠心枝を銀電極で吊り上げ、それら神経の電気活動を測定した。これらの測定値が落ち着いた時期(13時頃)に前記黒生姜抽出液を60%エタノールで500mg/kg投与量になるように溶解した原液を60%エタノールで100倍、1000倍、10000倍に希釈した液1mlをそれぞれ十二指腸に投与して自律神経活動の変化を電気生理学的に測定した。なお、対照実験としては溶媒である60%エタノール溶液1mlを十二指腸投与した。尚、手術開始から測定終了までチューブを気管に挿入して気道を確保し、保温装置にて体温(ラット直腸温)を35.0±0.5℃に保つようにした。自律神経活動のデータは5分間毎の5秒あたりの発火頻度(pulse/5s)の平均値にて解析し、刺激開始前の値(0分値)を100%とした百分率で表した。
(Sympathetic nerve activity evaluation test)
Wistar male rats (about 9 weeks old) having a body weight of about 300 g and kept in a constant temperature animal room at 24 ° C. for 1 week or more under a light / dark cycle every 12 hours (lighted from 8:00 to 20:00) were used. On the day of the experiment, after fasting for 3 hours, anesthetized with urethane, inserted a cannula for duodenal administration, then suspended the interscapular brown adipose tissue sympathetic nerve and the femoral cutaneous sympathetic nerve with a silver electrode, Electrical activity was measured. When these measured values settled (around 13:00), the stock solution obtained by dissolving the black ginger extract with 60% ethanol to a dose of 500 mg / kg was 100 times, 1000 times, and 10,000 times with 60% ethanol. 1 ml of the diluted solution was administered to the duodenum, and changes in autonomic nerve activity were measured electrophysiologically. As a control experiment, 1 ml of a 60% ethanol solution as a solvent was administered into the duodenum. A tube was inserted into the trachea from the start of surgery to the end of measurement to secure the airway, and the body temperature (rat rectal temperature) was maintained at 35.0 ± 0.5 ° C. with a heat retaining device. The data of autonomic nerve activity was analyzed by the average value of the firing frequency per 5 seconds (pulse / 5s) every 5 minutes, and expressed as a percentage with the value before the start of stimulation (0 minute value) as 100%.

図1に、60%エタノールで100倍、1000倍、10000倍に希釈した液によるマウスの肩甲間褐色脂肪組織交感神経活動(BAT−SNA)の経時変化を、図2に、60%エタノールで100倍に希釈した液による大腿皮膚動脈交感神経の活動の経時変化をそれぞれ示す。   FIG. 1 shows the time course of interscapular brown adipose tissue sympathetic nerve activity (BAT-SNA) in a solution diluted 100-fold, 1000-fold and 10000-fold with 60% ethanol, and FIG. The time-dependent change of the activity of the femoral cutaneous artery sympathetic nerve by the solution diluted 100 times is shown.

図1において、対照実験として行なった60%エタノール溶液1mlの十二指腸投与は最初徐々にBAT−SNAを低下させ、投与25分後にBAT−SNAを最低値74.4%に減少させ、その後徐々にBAT−SNAを上昇させて投与60分後にはBAT−SNAを101.7%にまで回復させた。これに対して、例えば、原液の100倍希釈液(5mg/kg相当を含む)1mlの十二指腸投与は、BAT−SNAを最初やや低下させて投与15分後にはBAT−SNAを70.2%にまで減少させたが、その後BAT−SNAを徐々に著明に上昇させて、投与60分後には176.7%にまで増加させた。   In FIG. 1, the duodenum administration of 1 ml of a 60% ethanol solution performed as a control experiment first gradually decreased BAT-SNA, and after 25 minutes of administration, BAT-SNA was decreased to a minimum value of 74.4%, and then gradually BAT -SNA was raised and BAT-SNA was recovered to 101.7% 60 minutes after administration. On the other hand, for example, the duodenal administration of 1 ml of a 100-fold diluted solution (including the equivalent of 5 mg / kg) initially reduced BAT-SNA slightly and reduced BAT-SNA to 70.2% 15 minutes after administration. After that, BAT-SNA was gradually increased markedly and increased to 176.7% 60 minutes after administration.

一方、原液を60%エタノールで1000倍、10000倍に希釈した、黒生姜の有効成分含有量がより少ない液においても、上記100倍希釈液の場合と同様にBAT−SNAの上昇が観察された。これらの結果から、黒生姜成分が、広い濃度範囲で、交感神経の活動を活発化させ得ることを確認することができた。   On the other hand, even when the stock solution was diluted 1000 times and 10000 times with 60% ethanol and the amount of the active ingredient content of black ginger was smaller, an increase in BAT-SNA was observed as in the case of the 100-fold diluted solution. . From these results, it was confirmed that the black ginger component can activate sympathetic nerve activity in a wide concentration range.

図2において、対照実験として行なった60%エタノール溶液1mlの十二指腸投与はCASNAを徐々に少しずつ上昇させ、投与60分後にはCASNAを最高値142.2%にまで増加させた。これに対し、原液の100倍希釈液(5mg/kg相当を含む)1mlの十二指腸投与もまた、CASNAを徐々に増加させて、投与55分後にCASNAを最高値163.6%にまで増加させた。   In FIG. 2, the duodenum administration of 1 ml of a 60% ethanol solution performed as a control experiment gradually increased CASNA little by little and increased CASNA to the maximum value of 142.2% 60 minutes after the administration. In contrast, the duodenal administration of 1 ml of a 100-fold dilution of the stock solution (including 5 mg / kg equivalent) also gradually increased CASNA and increased CASNA to a maximum value of 163.6% 55 minutes after administration. .

以上の実験結果より、黒生姜の抽出物の十二指腸投与が、対照実験として行なった60%エタノール溶液投与時と比較して、肩甲間褐色脂肪組織及び大腿皮膚動脈のいずれにおいても、その交感神経活動を増加させる作用を持つことを確認できた。   From the above experimental results, the duodenum administration of the black ginger extract showed its sympathetic nerve in both the interscapular brown adipose tissue and the femoral cutaneous artery compared to the 60% ethanol solution administration performed as a control experiment. It was confirmed that it has the effect of increasing the activity.

続いて、黒生姜エキスが500mg/kgとなるように水に懸濁した原液を、水によりさらに100倍に希釈して得た懸濁溶液を作成し、ラットの十二指腸に1ml与えるほかは、上記手順と同様にしてラットの肩甲間褐色脂肪組織(BAT−SNA)の活動の経時変化を観察した。また、対照実験として、希釈溶媒として使用した水1mlをラットの十二指腸に与えて、同様に肩甲間褐色脂肪組織の活動を観察した。図3に、その結果を示す。   Subsequently, a suspension obtained by further diluting the stock solution suspended in water so that the black ginger extract was 500 mg / kg was further diluted 100 times with water, and the above was given to the duodenum of the rat. Similar to the procedure, the time course of the activity of the rat interscapular brown adipose tissue (BAT-SNA) was observed. In addition, as a control experiment, 1 ml of water used as a dilution solvent was given to the duodenum of rats, and the activity of interscapular brown adipose tissue was similarly observed. FIG. 3 shows the result.

対照実験として行なった水の十二指腸投与は、BAT−SNAを殆ど変化させなかったのに対し、黒ショウガエキスの水懸濁液原液の100倍水懸濁希釈液1mlの十二指腸投与は、徐々に、しかし、著明にBAT−SNAを上昇させ、投与60分後には最高値の194.9%にまで増加させた。   The duodenal administration of water performed as a control experiment hardly changed BAT-SNA, whereas the duodenal administration of 1 ml of a 100 times aqueous suspension dilution of the black suspension of ginger extract was gradually However, BAT-SNA was significantly increased and increased to the maximum value of 194.9% 60 minutes after administration.

以上の実験結果より、黒生姜エキスの水懸濁溶液の十二指腸投与も、60%エタノール溶液の投与と同様にして、交感神経活動を増加させる作用を有することが確認された。   From the above experimental results, it was confirmed that the duodenal administration of the black ginger extract in water suspension also has the effect of increasing the sympathetic nerve activity in the same manner as the administration of the 60% ethanol solution.

さらに、上記の方法で得た黒生姜抽出液を乾燥した黒生姜エキス粉末、黒生姜粉砕物、及び黒生姜抽出液を用い、下記表の処方で飲料、顆粒、ソフトカプセル、美容液、シャンプー、石鹸を作成した。
(黒生姜粉砕物の製造)
黒生姜の根茎を洗浄後、1〜10mm程度にスライスし、1日天日干しにした。その後、40〜100℃に設定したオーブン乾燥機で4〜6時間乾燥し、粗粉砕後、130〜200℃で5〜20秒間殺菌を行った。殺菌した粗粉砕物を粉砕機によって粉砕し、黒生姜粉砕物を得た。
(黒生姜の茎、葉、花粉砕物の製造)
上記と同様の方法により、黒生姜の茎粉砕物、葉粉砕物、花粉砕物を得た。
Furthermore, using the black ginger extract powder, black ginger pulverized product, and black ginger extract obtained by drying the black ginger extract obtained by the above method, beverages, granules, soft capsules, cosmetic liquids, shampoos, soaps are formulated according to the following table. It was created.
(Manufacture of crushed black ginger)
After washing the black ginger rhizome, it was sliced to about 1 to 10 mm and dried in the sun for one day. Then, it dried for 4 to 6 hours with the oven dryer set to 40-100 degreeC, and sterilized at 130-200 degreeC for 5 to 20 second after coarse grinding. The sterilized coarsely pulverized product was pulverized by a pulverizer to obtain a black ginger pulverized product.
(Manufacture of black ginger stems, leaves, and pulverized flowers)
By the same method as above, a black ginger stem pulverized product, a leaf pulverized product, and a flower pulverized product were obtained.

実施例1(液剤の製造)
表1の配合割合で各成分を配合し、液剤とした。
Example 1 (Manufacture of a liquid agent)
Each component was blended at the blending ratio shown in Table 1 to obtain a liquid.

Figure 0005633028
Figure 0005633028

実施例2(顆粒1の製造)
表2に従い、スクラロース0.5kg、クエン酸5kg、還元麦芽糖水飴64.5kg、難消化性デキストリン67.2kg、カンゾウ抽出物0.5kg、黒生姜粉砕物16.8kg,シクロデキストリン8.4kg、ショウヤク5kgをフローコーターNFLO−200型流動層造粒機(フロイント産業(株)製)に投入し、数分間気流で混合する。これに、水60Lを1分間に2000mL噴霧することにより造粒を行った。つづいて、得られた造粒物を30メッシュの篩いにて篩別し顆粒剤とした。
Example 2 (Production of granules 1)
According to Table 2, sucralose 0.5 kg, citric acid 5 kg, reduced maltose starch syrup 64.5 kg, indigestible dextrin 67.2 kg, licorice extract 0.5 kg, black ginger ground product 16.8 kg, cyclodextrin 8.4 kg, shoyaku 5 kg is charged into a flow coater NFLO-200 fluidized bed granulator (manufactured by Freund Sangyo Co., Ltd.) and mixed with an air stream for several minutes. This was granulated by spraying 2000 mL of water for 1 minute. Subsequently, the obtained granulated product was sieved with a 30-mesh sieve to obtain granules.

Figure 0005633028
Figure 0005633028

実施例3(顆粒2の製造)
実施例2と同様にして、表3の成分を配合し顆粒剤とした。
Example 3 (Production of granules 2)
In the same manner as in Example 2, the ingredients shown in Table 3 were blended to prepare granules.

Figure 0005633028
Figure 0005633028

実施例4(ソフトカプセル1の製造)
表4の配合割合で配合した内容液を調製し、表5の配合割合で配合したカプセル皮膜に充填することでソフトカプセルとした。カプセル化は、カプセル皮膜液を流延しフィルム化するとともに、内部に内容液を充填しヒートシールし、成形されたソフトカプセルを乾燥させて行った。
Example 4 (Production of soft capsule 1)
The content liquid mix | blended with the mixture ratio of Table 4 was prepared, and it was set as the soft capsule by filling the capsule membrane | film | coat mix | blended with the mixture ratio of Table 5. Encapsulation was performed by casting a capsule coating solution to form a film, filling the content solution inside, heat-sealing, and drying the formed soft capsule.

Figure 0005633028
Figure 0005633028

Figure 0005633028
Figure 0005633028

実施例5(ソフトカプセル2の製造)
表6の配合割合で配合した内容液を調製し、表7の配合割合で配合したカプセル皮膜に充填し、実施例4と同様にしてソフトカプセルとした。
Example 5 (Production of soft capsule 2)
The content liquid blended at the blending ratio shown in Table 6 was prepared, filled into the capsule film blended at the blending ratio shown in Table 7, and soft capsules were obtained in the same manner as in Example 4.

Figure 0005633028
Figure 0005633028

Figure 0005633028
Figure 0005633028

実施例6(美容液の製造)
表8の配合割合で各成分を配合し、美容液とした。
Example 6 (Manufacture of serum)
Each component was blended at the blending ratio shown in Table 8 to obtain a cosmetic liquid.

Figure 0005633028
Figure 0005633028

実施例7(シャンプーの製造)
表9の配合割合で各成分を配合し、シャンプーとした。
Example 7 (Production of shampoo)
Each component was mix | blended with the mixture ratio of Table 9, and it was set as the shampoo.

Figure 0005633028
Figure 0005633028

実施例8(石鹸の製造)
表10の配合割合で各成分を配合し、石鹸とした。
Example 8 (Manufacture of soap)
Each component was blended at a blending ratio shown in Table 10 to obtain a soap.

Figure 0005633028
Figure 0005633028

Claims (2)

黒生姜加工物品を含有することを特徴とする交感神経活発化剤(だだし、胃腸の活動の抑制、消化液分泌の抑制、体温の上昇及び体重の減少を目的に使用するものを除く)A sympathetic nerve activator characterized by containing black ginger processed products (except for those used for the purpose of suppressing gastrointestinal activity, suppressing digestive secretion, increasing body temperature and losing body weight) . 前記黒生姜加工物品が黒生姜の根茎を利用したものである請求項1の交感神経活発化剤。 2. The sympathetic nerve activator according to claim 1, wherein the black ginger processed article uses a black ginger rhizome.
JP2013143531A 2012-07-10 2013-07-09 Sympathetic nerve activator Active JP5633028B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013143531A JP5633028B2 (en) 2012-07-10 2013-07-09 Sympathetic nerve activator

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012154966 2012-07-10
JP2012154966 2012-07-10
JP2013143531A JP5633028B2 (en) 2012-07-10 2013-07-09 Sympathetic nerve activator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014151767A Division JP6355248B2 (en) 2012-07-10 2014-07-25 Sympathetic nerve activator

Publications (2)

Publication Number Publication Date
JP2014031367A JP2014031367A (en) 2014-02-20
JP5633028B2 true JP5633028B2 (en) 2014-12-03

Family

ID=50281502

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013143532A Active JP5928732B2 (en) 2012-07-10 2013-07-09 Brown adipocyte activator
JP2013143531A Active JP5633028B2 (en) 2012-07-10 2013-07-09 Sympathetic nerve activator
JP2014151767A Active JP6355248B2 (en) 2012-07-10 2014-07-25 Sympathetic nerve activator
JP2014202055A Active JP6211500B2 (en) 2012-07-10 2014-09-30 Brown adipocyte activator

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013143532A Active JP5928732B2 (en) 2012-07-10 2013-07-09 Brown adipocyte activator

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014151767A Active JP6355248B2 (en) 2012-07-10 2014-07-25 Sympathetic nerve activator
JP2014202055A Active JP6211500B2 (en) 2012-07-10 2014-09-30 Brown adipocyte activator

Country Status (1)

Country Link
JP (4) JP5928732B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5845526B2 (en) * 2014-05-14 2016-01-20 株式会社東洋新薬 Water-soluble composition containing black ginger
JP5849272B1 (en) * 2014-09-10 2016-01-27 株式会社東洋新薬 Composition for promoting PPARγ expression containing black ginger
JP6447972B2 (en) * 2015-05-07 2019-01-09 株式会社東洋新薬 Composition for promoting PPARγ expression containing black ginger
JP6765090B2 (en) * 2019-05-14 2020-10-07 株式会社東洋新薬 Black ginger-containing composition
JP7081843B2 (en) * 2020-10-26 2022-06-07 株式会社東洋新薬 Autonomic nerve regulator

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007097547A (en) * 2005-10-07 2007-04-19 Chiba Univ Method for screening obesity-treating agent or obesity-preventing agent
JP2009051790A (en) * 2007-08-29 2009-03-12 Maruzen Pharmaceut Co Ltd Antioxidant, anti-aging agent, anti-inflammatory agent, hair restoration agent, anti-obesity agent, skin-lightening agent, cosmetic and food and drink for cosmetic use
JP2009067731A (en) * 2007-09-14 2009-04-02 Office K:Kk Composition for improving cold constitution

Also Published As

Publication number Publication date
JP2014198732A (en) 2014-10-23
JP2014031367A (en) 2014-02-20
JP2014031368A (en) 2014-02-20
JP6355248B2 (en) 2018-07-11
JP6211500B2 (en) 2017-10-11
JP5928732B2 (en) 2016-06-01
JP2014240442A (en) 2014-12-25

Similar Documents

Publication Publication Date Title
JP6064156B2 (en) Deep body temperature raising agent
JP5633028B2 (en) Sympathetic nerve activator
JP2010209051A (en) Fat absorption inhibitor
US10111451B2 (en) Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor
KR20190013575A (en) composition for preventing of hair loss or promoting hair growth
JP2007277183A (en) Composition having brain cell-activating effect by virtue of ginkgo leaf extract nano fine particle
JPH09208484A (en) Active oxygen-eliminator and composition containing the same
JP2015027998A (en) Moisturizer, skin barrier function activator, tight junction formation accelerator, trpv4 expression enhancer, intracellular calcium concentration increaser, intracellular calcium concentration increaser, lipid synthesis accelerator, blood flow improver and periocular darkness ameliorator
EP4205558A1 (en) Health functional food, comprising siberian chrysanthemum extract, for pain relief or antioxidation
JP6765090B2 (en) Black ginger-containing composition
KR101964249B1 (en) Composition for preventing, improving or treating atopic dermatitis comprising mixture of Torilis japonica extract and copper tripeptide-1 as effective component
KR102209663B1 (en) Composition for preventing or treating skin disease comprising extract of Spiraea prunifolia simpliciflora
KR20170100100A (en) A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia
JP2016160198A (en) Kaempferia parviflora-containing compositions
WO2022169066A1 (en) Functional collagen composition using aurea helianthus-derived collagen amino acid
CN108653716A (en) A kind of tealeaves essence drunk-sobering tablet and preparation method thereof
JP7228544B2 (en) A composition for preventing or treating nicotine addiction, comprising an extract of Liriope platyphylla as an active ingredient
WO2008069604A1 (en) Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease
JP6541061B2 (en) Composition for promoting clock gene expression
KR20160082958A (en) Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient
JP6926378B2 (en) Microdust phagocytosis accelerator
KR102209664B1 (en) Composition for preventing or treating skin disease comprising extract of Euonymus alatus ciliatodentatus
JP2020193230A (en) Kaempferia parviflora-containing compositions
JP2017222616A (en) Autonomic nerve regulating agent
JP6151027B2 (en) Ceramide production promoter

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131212

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20131212

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140725

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140917

R150 Certificate of patent or registration of utility model

Ref document number: 5633028

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250